Objective: To analyze gastrointestinal (GI) manifestations, their progression over time, and medications being used to treat GI symptoms in a large cohort of patients with myotonic dystrophy types 1 (DM1) and 2 (DM2).
In this study, we analyze GI manifestations and their progression in large cohorts of patients with DM1 (n 5 913) and DM2 (n 5 180) enrolled in the NIH-sponsored National Registry of Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Patients and Family Members. 12 METHODS Enrollment process of the National Registry and cohort selection. The registry has enrolled patients since September 2000 (ClinicalTrials.gov identifier NCT00082108). 12 The registry is located at the University of Rochester (Rochester, NY).
Applications to enroll in the registry consist of a patientreported questionnaire that collects disease-specific data, a Release of Medical Information Form, and Patient Consent Forms. 12 Eligibility is determined when registry staff and leadership establish the diagnostic classification of each patient on the basis of a review of their clinical examinations, EMG and muscle biopsy reports, and results of genetic testing. 12 Members of the Scientific Advisory Committee developed the diagnostic classifications for registry members for genetically and clinically confirmed patients. 13 Annual update forms are sent to members yearly to track changes in patient-reported outcomes.
In this study, deidentified data were analyzed from patients enrolled in the registry who were at least 18 years old, US citizens, and classified with genetically proven or clinically defined DM1 or DM2. 12 Patients analyzed in this study were enrolled in the National Registry from 2002 to 2016. Patients with congenital DM of any age were excluded from analyses.
Standard protocol approvals, registrations, and patient consents. The Human Subjects Review Board of the University of Rochester Medical Center approved the protocol and all forms associated with the registry. All members of the registry provided written informed consent at enrollment.
Characteristics of the registry participants. Demographic and clinical information in the registry included age, sex, age at symptom onset, body mass index (BMI), years since symptom onset, and CTG (DMPK gene) or CCTG size (CNBP gene). The lengths of the repeats were derived from medical record review. Patient-reported GI manifestations were categorized on the questionnaire at baseline as trouble with swallowing, acid reflux or heartburn, gallbladder trouble (including gallbladder surgery), stomach ulcer, liver trouble, constipation, and other. The questions related to GI manifestations are asked on the form as follows: "Have you ever had or do you have any of these conditions?"
Information on current GI medication use was also collected, including name of the medication, duration of use, and daily dosage. We reviewed the medical records of the patients who reported liver problems to extract data on their specific conditions. Progression of GI symptoms was documented from the annual update forms. For the longitudinal dataset, we analyzed eligible members of the registry who had completed an updated form 5 years after baseline. The question on the form reads, "Have you ever had or do you have any of these conditions?" We describe the percentage of patients who did not have the symptom at baseline and then reported it by year 5.
Statistical analyses. We used t tests and x 2 tests to compare baseline demographic and clinical characteristics between patients with DM1 and those with DM2.
Logistic regression analyses were performed to determine whether select demographic/clinical variables were associated with GI manifestations at baseline separately in patients with DM1 and DM2. The variables analyzed include sex, age, BMI, symptom duration, smoking, and CTG or CCTG repeat size. The results of these analyses are reported as odds ratios (ORs), their associated 95% confidence intervals (CIs), and p values.
A significance level of 0.05 was used for all hypothesis tests. GI manifestations at baseline. At baseline, 79% (n 5 721 of 913) of patients with DM1 and 77% (n 5 139 of 180) of patients with DM2 reported a history of $1 GI manifestations (figure e-1 at Neurology.org). Only 1.3% of patients with DM1 and none of the patients with DM2 reported a GI problem as the initial manifestation of their disease. The most common GI manifestation in DM1 was trouble swallowing (55%, n 5 499 of 913), whereas the most common GI symptom in DM2 was constipation (53%, n 5 96 of 180; figure 1 ). Combining the GI manifestations classified as other in patients with DM1 and DM2, we identified 1.7% (n 5 19 of 1,093) of DM patients with a history of irritable bowel syndrome (IBS), 1.3% (n 5 14 of 1,093) with diarrhea, and ,3 patients each with lactose intolerance, obstruction, fecal incontinence, abdominal pain, megacolon, upset stomach, and spasms/delayed gastric emptying. Similar frequencies of liver problems occurred in 5.8% of patients with DM1 (n 5 53 of 913) and 8.3% of patients with DM2 (n 5 15 of 180) (p 5 0.20). We reviewed the medical records for all 68 patients with liver problems. The majority of records from these patients were obtained from neurologists (70.6%, n 5 48 of 68). Abnormal liver problems were noted in the medical records of 34 patients. Fifty percent of these patients (n 5 16 of 34) had elevated liver enzyme levels, 20.6% (n 5 7 of 34) had evidence of fatty liver disease, and 16.1% (n 5 5 of 34) had hepatitis C. Two patients (5.9%, n 5 2/34) had liver tumors that were not otherwise specified, and 4 patients were noted for having hepatitis B, hepatitis not otherwise specified, autoimmune hepatitis, or a "prediabetic" liver conditions (2.9%, n 5 1 of 34).
RESULTS

Characteristics
Of the patients with DM1 with liver problems (n 5 53), 41.5% (n 5 22 of 53) also had gallbladder problems. In the patients with DM2 with liver problems (n 5 15), the co-occurrence of gallbladder problems was less frequent (20%, n 5 3 of 15). Cholecystectomy had been performed in 16.5% (n 5 151 of 913) of patients with DM1. The mean age at the time of gallbladder removal was 38.1 6 10.9 years. More women (20.0%, n 5 96 of 479) than men (12.7%, n 5 55 of 434) with DM1 reported having a cholecystectomy. For patients with DM2, 12.8% (n 5 23 of 180) reported a cholecystectomy at a mean age of 43.7 6 13.3 years. Cholecystectomy was reported by more women (16.2%; n 5 18 of 111) than men (7.2%; 5 of 69) with DM2.
Variables associated with GI manifestations. Female sex was significantly associated with a history of constipation at baseline in both DM1 (OR 2.14, 95% CI 1.61-2.85, p , 0.001) and DM2 (OR 3.12, 95% CI 1.67-5.84, p , 0.001) (table e-1). In addition, female sex was associated with a history of gallbladder problems at baseline in patients with DM1 (OR 1.59, 95% CI 1.14-2.23, p , 0.01) and with a history of acid reflux at baseline in patients with DM2 (OR 2.35, 95% CI 1.26-4.39, p , 0.01) (table e-1).
Higher BMI was associated with histories of acid reflux, gallbladder trouble, and liver trouble in patients with DM1 (table e-1). Patients with DM1 with longer symptom duration were at greater risk of having histories of trouble swallowing, constipation, gallbladder trouble, and liver trouble at baseline (table e-1). Older patients with DM1 were at increased risk of a history of gallbladder trouble and liver trouble at baseline (table e-1) .
No other variables were associated with a history of GI manifestations in patients with DM1 or DM2 (table e-1).
Medications used to manage GI manifestations. We identified 59 medications being used to treat GI manifestations in the DM1 cohort and 28 GI-related medications in the DM2 cohort. The medications Percentages of patients with DM1 and DM2 who reported GI manifestations at enrollment in the registry
Percentages are from totals of the baseline cohort of 913 patients with DM1 and 180 with DM2. DM 5 myotonic dystrophy; GI 5 gastrointestinal. *Significant difference between the DM1 and DM2 baseline cohorts (p , 0.001).
are classified by indication in DISCUSSION Our data support the hypothesis that GI manifestations are common in DM1 and DM2. 11 During the 5 years of follow-up, the most common changes were new reports of stomach ulcers and trouble swallowing in patients with DM1 and the development of trouble swallowing and constipation in patients with DM2.
Dysphagia often exacerbates risks of pneumonia, decreases nutritional intake, and reduces quality of life. 14, 15 Unfortunately, literature reviews indicate little consensus on the pathophysiology, assessment, and management of dysphagia in neuromuscular disorders.
14,15 Diagnostic approaches include a detailed medical history, clinical examination, and multidisciplinary tests such as manometry, videofluoroscopy, and fiberoptic endoscopic evaluation of swallowing. 14, 15 Additional studies are needed to assess the reliability of these tests and their ability to detect changes over time. Examples of management of dysphagia include dietary changes, exercise, and rehabilitation strategies that focus on quality-of-life issues and safety. 14, 15 The emergence of constipation also complicates disease management and reduces quality of life in patients. Prior research suggests that patients with DM1 often report stomach pain, bloating, and fluctuations between diarrhea and constipation that are similar to IBS. 1, 7 Other small intestine and colon concerns in DM include bacterial overgrowth, pseudoobstruction, and bile acid malabsorption. 1, 7 One study showed positive results of antibiotic treatment of bacterial overgrowth in patients with DM1. 16 In an uncontrolled clinical trial, 3 patients with DM1 with severe IBS showed marked improvement after 24 weeks of recombinant human insulin-like growth factor (IGF)-1 complexed with IGF binding protein-3. 17 More studies are needed to determine whether similar IGF-1-like compounds or other growth factors may improve IBS-like symptoms in DM. Proposed pathomechanisms of both diarrhea and constipation in DM include endocrine disturbances, smooth and striated muscle dysfunction, myotonia, inflammation, and alterations in motility. 7 Similar mechanisms may help explain the high frequency of gallbladder problems and cholecystectomy reported in the patients with DM1 and DM2. Our data corroborate previous findings of studies that assessed smaller samples of patients with DM1 only. [18] [19] [20] [21] Moreover, our study shows that members of the registry had their gallbladder removed z10 years earlier on average than individuals in the general population based on available normative data. 22 Additional studies are needed to confirm our findings and to determine the risks of cholecystectomy at a comparatively younger age in patients with DM1 and DM2, including potential bile duct injury, hemorrhage, pulmonary insufficiency, atelectasis, and other DM-related anesthesia complications. Studies are also needed to assess the pathophysiology of the gallbladder problems in patients with DM1 and DM2. One research team analyzed gallbladder tissue in a 30-year-old patient with DM1 who underwent elective cholecystectomy for chronic gallbladder disease. 23 The researchers found alterations of muscleblind-like proteins in the smooth muscle of the gallbladder. 23 This finding is typical of the skeletal and cardiac muscle molecular pathology in DM1. The presence of bound muscleblind-like mutant DM mRNA inclusions in the smooth muscle of the gallbladder supports the hypothesis that RNA toxicity, perhaps related to its role in causing a decreased production of chloride channel protein, may lead to altered function of gallbladder smooth muscle. Such alterations may decrease normal contractility of the gallbladder and contribute to the formation of gallstones. 23 Studies are also needed to assess the pathomechanisms of gallbladder dysfunction in DM2 and to compare the pathophysiology to DM1.
Another concern is that z40% of our patients with DM1 and DM2 reported acid reflux. GERD occurs in 18.1% to 27.8% in general US cohorts. 24 Untreated GERD often reduces health-related quality of life, impairs sleep, alters eating habits, and reduces productivity at work. 25 Pharmacologic treatment of GERD consists of acid suppression drugs, prokinetics, histamine receptor type 2 antagonists, and proton pump inhibitors. 26 Proton pump inhibitors are the most effective treatments for GERD and account for z77% of the market for GI medications. 27 Long-term use of proton pump inhibitors poses several adverse side effects to balance against their benefits. 26 Examples of risks include hypomagnesemia, pneumonia, Clostridium difficile infections, fractures, acute and chronic kidney disease, and dementia. 26, 28 To the best of our knowledge, no clinical trials have evaluated the efficacy and safety of various formulations of proton pump inhibitors in patients with DM1 and DM2. No clear clinical guidelines exist on length of treatment needed in DM. There are issues specific to their use in DM1 and DM2 such as how other disease manifestations may interact with such medications and potential socioeconomic and compliance factors that may hinder their use. 29 Further studies are necessary to evaluate alternative treatment approaches such as nutrition, exercise, and weightloss counseling alone or in conjunction with GERD medications.
Women with DM1 were at greater risk than men for constipation and gallbladder problems. Our data support findings from a recent study in a large sample of French patients with DM1. 30 In that study, the researchers reported that a higher percentage of female participants had digestive tract dysfunction, defined as either constipation or diarrhea. 30 A higher percentage of women with DM1 also reported more cataracts, dysphagia, incontinence, thyroid dysfunction, and obesity compared to men. 30 The authors highlight previous research linking differences between men and women to variabilities in gene expression and metabolism of skeletal muscle, increased oxidative stress (e.g., in cardiovascular disease), and hormonal effects on myotonia. 30 A literature review focuses on varying mitochondrial dysfunctions between men and women, in particular, highlighting sex differences in patients with amyotrophic lateral sclerosis, Parkinson disease, and Alzheimer disease. 31 Other researchers report a greater frequency of certain types of cancers in female compared to male patients with DM1. 32, 33 One of these studies suggests that cancer risk, especially in women, is related to changes in downstream regulation of specific cancer genes instead of a direct effect of the DMPK mutation. 32 In the present study, no associations were found between repeat sizes in the DMPK or CNBP mutant genes in circulating leukocytes and the GI manifestations in our cohorts. A prior study of 15 patients with DM1 showed a correlation between CTG repeat sizes and severity of swallowing measured by videofluoroscopy. 34 Other investigators have observed no associations between the severity of skeletal muscle damage and GI disturbances. 35, 36 Data from the registry support previous studies that show an association between disease duration and GI manifestations in DM1. 36, 37 More research is needed to better assess biomarkers and other predictors of GI manifestations in DM. Table 4 Frequencies of patients with DM2 reporting GI manifestations at 5-year follow-up (n 5 89 within the DM2 follow-up cohort)
History of symptom at enrollment, n/N (%) The strengths of our study include cohorts of patients with a broad range of disease severity and age at onset; diverse demographics, including sex, age, and a broad geographic representation within the United States; stringent review of clinical and genetic medical records to verify disease classification; and annually updated information up to a maximum of 13 years. 12 There are also limitations to our study. One limitation is that these GI manifestations are patient reported. These manifestations may actually be underreported because patients often do not attribute their GI manifestations to DM. We often prompt patients in clinic to discuss GI manifestations, especially patients with DM1 who are more severely affected and have cognitive or apathetic personality related to their disease. 38 More detailed information from clinical examinations and diagnostic testing is needed to confirm and expand our results. Another limitation is the lack of information on risk factors of the patients who have experienced GI manifestations (e.g., stress, diet, family history). A follow-up questionnaire is needed to expand on our data to assess comorbidities and lifestyle factors that increase the risk of GI disturbances and the exact timing of their onset. The registry is tailored to allow easy recruitment of patients to participate in such future questionnairebased studies.
Another limitation is that our cohorts may be less severely affected than the overall populations of patients with DM1 and DM2. A future opportunity is to partner with international registries to compare GI manifestations in larger patient cohorts and across broader socioeconomic backgrounds and nationalities. Such collaborations may also facilitate the development of studies to bridge patient-reported data with studies on how GI disturbances may or may not relate to our current understanding of RNA toxicity in DM and better ways to assess future targeted therapies. 39 
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